Moreover, the SUMMIT trial [30] recently showed that tirzepatide, a dual GLP-1/GIP receptor agonist, significantly reduced the risk of cardiovascular death or HF worsening and improved quality of life in patients with HFpEF and obesity. The gene discussed is GLP1R; the disease is hydrops fetalis.